Geller Biopharm Exclusively Represents HepaTx for Licensing and Financing

November 3, 2021

Palo Alto, CaliforniaHepaTx to present at the next the American Association for the study of Liver Diseases Meeting (AASLD) - HepaTx, a biotechnology company focused on innovative off-the-shelf cell therapy to treat severe late-stage liver disease, is pleased to announce that Eric Schuur, PhD, CSO and COO, will be presenting next week at the Liver Meeting – Digital Experience, from the 12th to the 15th of November, organized by the American Association for the Study of Liver Diseases (AASLD).

Dr. Schuur will be presenting the latest in-vitro and in-vivo results for their next-generation cell therapy treatments for severe acute liver injury and chronic liver disease, employing their proprietary off-the-shelf cell therapy technology. “These data are an important step in preparing our product candidates for future human clinical trials. I want to congratulate Eric and our entire scientific staff at HepaTx for their hard work and dedication to advancing HepaTx cell therapies toward our goal of helping those individuals suffering from Liver disease who currently have limited therapeutic options,” said Salah Kivlighn, PhD. CEO at HepaTx.

About HepaTx’s Platform: - HepaTx is developing a proprietary platform that differentiates adipose stromal cells obtained from lipoaspirate into functional hepatocytes-like cells without genetic manipulation of cells. Off-the-shelf, ready for immediate use, hepatocyte-like cells which may be directly infused into the liver where they have the potential to preserve and regenerate liver function. The platform is designed to be scalable to meet expected demand of major unmet medical needs in liver disease.

About HepaTx: - HepaTx is a regenerative medicine company developing new types of stem cell-based treatments for patients with severe acute liver injury, late-stage liver disease and a broad pipeline including expansion into NASH, chronic decompensated liver failure, cirrhosis, and other liver-focused indications with large unserved markets. The technology is licensed from Stanford and well protected by global issued IP. To learn more, visit our website, and follow us on Twitter, @hepatx.

Contacts Claudia Preziosi,
BD Manager,

Geller Biopharm

  Broker / Dealer services provided by Pickwick Capital Partners, LLC. Member FINRA / SIPC

Download our presentation

Get a digital copy of our PDF presentation

Download PDF